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1. Introduction 
Autoimmune diseases occur when an individual develops an immune response targeted 
against specific organ or number of organs. Genetic susceptibility and environmental factors 
are the main responsible of the development of the autoimmune process leading to a 
clinically evident disease.  
The majority of organ-specific autoimmune diseases are characterized by an initial 
infiltration by lymphocytes and macrophages, of the organ,  with impaired activity of the 
organ  followed by atrophy. This progressive autoimmune  process takes time, and is T cell 
mediated. Antibodies against specific antigens of the involved gland are detectable in the 
blood before the clinical onset of the specific disease, so they represent a risk marker and 
their screening and follow-up allow precocious diagnosis and treatment of autoimmune-
related disease in genetically susceptible individuals (Allen et al., 2008).  
Genetic factors and autoimmunity are closely related since the developmental maturation of 
T cells occurs through an interaction between HLA antigen and T cell receptor. In 
genetically susceptible individuals, disease-prone HLA molecules are ineffective at binding 
and presenting peptides from tissue-specific antigens, therefore auto-reactive T cells can 
survive and trigger a poorly regulated  immune response thereafter (Van den Driessche, 
2009). 
Patients affected by type 1 diabetes mellitus are at increased risk of developing other 
autoimmune conditions like celiac disease, autoimmune thyroid disease, adrenal 
insufficiency, atrophic gastritis, autoimmune hepatitis, primary ovarian failure.  
The frequency of organ specific autoimmunity in patients with type 1 diabetes might be due 
to multiple immunologic abnormalities, i.e an imbalance in B and T lymphocytes, or a 
tendency to react against specific antigens, or poor ability to develop immune tolerance.   
2. Type 1 diabetes mellitus 
2.1 Background 
Type 1 diabetes mellitus is the most common endocrinopathy to have clinical onset in 
childhood or adolescence, with varied pathogenesis, clinical appearance and outcome,  and 
seriously affects patients’ and families’ life. A combination of genetic, environmental and 
immunological factors exerts to a T-cell mediated autoimmune process targeted against 
insulin-producing -cells in the pancreatic islet of Langerhans (Daneman, 2006).  
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2.2 Epidemiology 
The incidence of Type 1 diabetes is increasing worldwide and may double the burden of the 
disease in youngest children by 2020. Large collaborative studies like DiaMond and 
EURODIAB Registries demonstrated that one century ago childhood diabetes was rare and 
fatal, while at the end of the century a steady increase in several parts of the world has been 
observed. In particular, DiaMond Project reported the trend in incidence of Type 1 diabetes  
from 1990 to 1999; over this period the average annual increase in incidence was 2.8%, with 
a slight higher rate in the last 5 year-period as compared to the first 5-year period. Similarly, 
EURODIAB Study reported a 3.9% annual increase from 1989-2003 (Vehil & Dabelea, 2011). 
The rising incidence of Type 1 diabetes over the past decades is too quick to be attributed to 
an increased genetic susceptibility, since the proportion of newly-diagnosed patients 
carrying the highest-risk HLA genotype (HLA DR3/DR4) seems unchanged.  
2.3 Pathogenesis  
Genetic susceptibility plays an important pathogenetic role in type 1 diabetes mellitus, with 
the HLA -DR and –DQ genes explaining about 50% of the risk. The different penetrance of 
these genes can partially explain the role of environmental factors. Whereas differences in 
incidence between populations may be due to genetic susceptibility or protection genes, the 
increasing incidence is to be ascribed to environmental factors. Studies aimed to analyze the 
temporal changes in the frequency of genotypes associated with type 1 diabetes 
susceptibility reported a decreasing frequency of those higher-risk HLA genotypes (DRB1 
03-DQA1*0501-DQB1*0201/DRB104-DQA1*0301-DQB1*0302) between recently diagnosed 
patients as compared to those diagnosed 50 years before (Hermann et al., 2003). Therefore 
the increasing incidence of type 1 diabetes could be explained by a more permissive 
environment, exerting in increased penetrance of low/moderate risk genotypes or in 
interplay between environmental factors and other non-HLA genes (Nejentsev et al., 2007, 
Todd et al., 2007). On the other hand, several environmental factors such as dietary habits, 
sedentary lifestyle, climate changes, pollution, viral (also maternal) and other infectious 
disease frequency and type, have changed over the past years and deserve attention 
(Oikarinen et al., 2011). 
The immune-mediated -cell destruction occurs over several years and exerts in progressive 
insulin deficiency, leading to various degrees of hyperglycemia up to severe metabolic 
derangement , i.e. diabetic ketoacidosis (Devendra et al., 2004).  
Studies in both humans and animal models are trying to clarify the specific antigenic targets 
involved in the islet cell autoimmunity. Islet cell antibodies (ICA) detected by 
immunofluorescence, were firstly isolated in patients with diabetes mellitus and 
autoimmune polyglandular syndrome (Bottazzo et al., 1974). These autoantibodies are 
transient, being observed in 70-80% of newly-diagnosed cases and tend to disappear 
thereafter. Their positivity in subjects at risk of diabetes (i.e. first-degree relatives) represents 
a useful means to predict the future development of the disease.  
Anti-insulin autoantibodies (IAA) can be detected both by radioimmunoassay (RIA) or by 
ELISA, but the first method is recommended. IAA positivity is inversely related to age at 
diabetes diagnosis (81% in patients younger than 10 and 61% in older ones), and is higher 
and adolescent males (Williams et al., 2003). IAA are the first autoantibodies to became 
positive, and they can later decline. Interestingly, substitutive insulin therapy can be 
followed by an immune response against itself, and this subtype of insulin antibodies can be 
distinguished from anti-insulin autoantibodies.  
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In 1990 Baekkeskov and co-workers reported that the 64,000 M (R) molecule previously 
defined as an antigenic target of Type 1 diabetes was the GABA-synthesizing enzyme 
glutamic acid decarboxylase (GAD) (Baekkeskow et al., 1990). GAD is not expressed 
exclusively on -cells, but also in other islet cells. Anti-GAD autoantibodies (GADA) can be 
detected both by RIA or by ELISA. The prevalence of anti-GAD autoantibodies positivity is 
84%, and is positively related to age and female sex. Their peak level can be reached after 
diabetes diagnosis and persist longer than anti-islet cell antibodies, making them a useful 
marker especially for adult patients.  
In 1994 a cDNA coding a 548 aminoacid protein named ICA-512 was described as a major 
target of humoral immunity by screening an islet c-DNA expression library with patients’ 
sera (Rabin  et al., 1994). Moreover it has been reported that IA-2, a 979 aminoacid 
transmembrane protein of the tyrosine phosphatase family, is a major autoantigen in type 1 
diabetes. IA-2 is a intrinsic membrane protein of secretory granules neuroendocrine cells, 
like pancreatic islets. IA-2 autoantibodies (IA-2A) can be detected by RIA as well as by 
ELISA. Recently a not radio-isotopic method (time-resolved immunofluorometric assay (TR-
IFMA) showed comparable results with RIA. The prevalence of IA-2A has been reported 
about 73%, and no correlation with age was found (Tsirogianni et al., 2009).  
Recently the cation efflux transporter 8 (ZnT8) has been identified as a novel target auto-
antigen in patients with type 1 diabetes. Autoantibodies to ZnT8 (ZnT8 A) are detectable in 
about 70% of newly diagnosed patients, independent of age (Achenbach et al., 2009). 
Patients presenting with a single islet cell autoantibody were also positive for ZnT8 A, 
suggesting that they could be a marker for type 1 diabetes risk stratification. Three variants 
of ZnT8 A have been recognized:  1) ZnT8RA (arginine 325 zinc transporter 8 autoantibody), 
2) ZnT8WA (tryptophan 325 zinc transporter 8 autoantibody), 3) ZnT8QA (glutamine 325 
zinc transporter 8 autoantibody). These 3 ZnT8 variants precede T1DM clinical onset and 
are all detectable by radio-binding assay (Andersson et al., 2011).  
2.4 Diagnosis and treatment 
Diagnosis of type 1 diabetes is based on symptoms of hyperglycemia: polyuria, polydipsia, 
with mild symptoms up to severe ketoacidosis. After intravenous fluid, insulin and salt 
replacement for metabolic imbalance recovery, treatment of type 1 diabetes consists of 
lifelong substitutive subcutaneous insulin therapy, together with correct dietary habits, self-
management of the disease and regular physical activity, as result of a prolonged 
educational intervention starting at the time of clinical diagnosis (Maffeis & Pinelli, 2008, 
Bangstad et al., 2007). Recognition, management and prevention of hypoglycemic episodes 
as well as hyperglycemic spikes is mandatory. Continuous education implementation 
starting at the time of clinical diagnosis, designed for children, adolescents and their 
parents,  is necessary thereafter (Weinzimer et al., 2005).  
2.5 Follow-up 
The most serious problem related to pediatric type 1 diabetes is the risk, even in young 
adulthood, of microvascular and macrovascular complications, i.e. retinopathy, 
nephropathy, neuropathy, cardiovascular and cerebrovascular diseases (Donaghue et al., 
2007). The key role of good glycaemic control to prevent diabetes-related complications has 
been firmly established by the Diabetes Control and Complications Trial  Study, which 
demonstrated the protective role of intensive insulin treatment (DCCT, 1993). Sustained 
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chronic hyperglycaemia and acute blood glucose fluctuations have a deleterious effect on 
the metabolic mechanisms involved in the development of microangiopathy, such as protein 
glycation and oxidative stress. In particular, glucose variability from peaks to nadir, with 
upward as in the postprandial periods, and nadirs, as in the interprandial periods activates 
the oxidative stress (Monnier & Colette, 2008). As regards  pediatric diabetes, despite better 
insulin preparations and strict self-management of the disease few children and adolescents 
maintain mean glycated hemoglobin A1c (HbA1c) levels within the normal ranges, with 
serious impact on metabolic control and subjects’ caregiver quality of life (Rewers et al, 
2009). 
3. Celiac disease 
3.1 Background and epidemiology 
Celiac disease is an immune-mediated disorder, the only one with a well-established causal 
agent, resulting from a permanent gluten intolerance triggered by the ingestion of the 
gliadin fraction of wheat gluten and similar alcohol-soluble proteins named prolamines of 
barley and rye (Di Sabatino & Corazza, 2009). Gluten intolerance exerts a chronic 
inflammatory lesion characterized by flattened villi of the small bowel mucosa and sub-
mucosa, with a diverse clinical heterogeneity ranging from asymptomatic disease to severe 
malabsorption syndrome in genetically susceptible individuals (Branski et al., 2006).  
Once considered a rare childhood disorder, celiac disease is now known to be a very 
common condition, even if it remains widely unrecognized and underdiagnosed worldwide 
both in children and in adults. Availability of new very sensitive and specific serological 
markers (initially anti-gliadin  and anti-reticulin antibodies, and thereafter anti-endomysial 
and anti-transglutaminase antibodies) allowed more efficient screening, independently from 
classical clinical picture. Thanks to these serological markers, celiac disease has been 
identified in a high proportion of children adolescents and adults who did not previously 
received a correct clinical diagnosis. The prevalence of celiac disease was dramatically 
increased, and defined as 1 case in 99 schoolchildren in Finland  (Mäki et al., 2003), and 1 in 
106 in Italy (Tommasini et al., 2004). 
3.2 Pathogenesis 
Celiac disease develops from the interplay between a well-defined environmental factor and 
genetic susceptibility, with the participation of other causative cofactors (drugs like 
interferon-, infectious agents like intestinal rotavirus, modifications in infant-feeding 
timing) (Di Sabatino & Corazza, 2009).  
The causal agent, for CD are specific immunogenic peptides present exclusively in the dietary 
gluten proteins, from wheat and other cereals like rye and barley. Gluten proteins  can be 
divided into 2 fractions, gliadins and glutenins, both characterized by immunogenicity and 
by toxicity. Among gluten immunostimolatory peptides, some are more active than others. 
In particular, a 33 aminoacid immuno-dominant peptide identified from an -gliadin 
fraction has functional  properties attributable to many proline and glutamine residues. 
Proline increases the peptide resistance to gastrointestinal proteolysis, with more strength 
binding with HLA-DQ2 and HLA-DQ8 molecules on antigen presenting cells. Glutamine 
residues are a preferred substrate for transglutaminase-mediated deamination, with 
subsequent increased immunogenicity (Shan et al., 2002).  
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Genetic factors play an important pathogenetic role, as demonstrated by a concordance rate 
of 85% in monozygotic twins and by familiar aggregation. HLA-DQ genes, in particular  
DQ2 variant (alleles DQA1*05/DQB1*02) and DQ8 variant (alleles DQA1*03/DQB1*0302) 
are strongly associated to  CD. Beside the HLA genes (i.e. COELIAC 1, on chromosome p21), 
other non-HLA genes are recognized to confer additional susceptibility: COELIAC 2, on 
chromosome 5q31-33, which contains cytokine gene clusters; COELIAC 3, on chromosome 
2q33, which codes the negative co-stimulatory molecule CTLA4; COELIAC 4, on 
chromosome 19p13.1,  which contains the myosin IXB gene variant encoding a myosin that 
alters actin remodeling (Di Sabatino & Corazza, 2009).  
As regards pathophysiology od CD, it has been demonstrated that gluten peptides, which are 
resistant to digestion by gastric and pancreatic enzymes, after crossing intestinal epithelium, 
are deaminated by tissue transglutaminase and then presented by DQ2+ or DQ8+  antigen-
presenting cells to gluten-specific CD4+ T cells. These cells once activated drive a Th1 
response, characterized by  production of pro-inflammatory cytokines, and responsible for 
the development of celiac lesions, i.e. lamina propria infiltration of inflammatory cells, crypt 
hyperplasia and villous atrophy (Di Sabatino & Corazza, 2009). 
3.3 Clinical presentation and diagnosis 
The clinical range of celiac disease has a wide spectrum, from asymptomatic to severe 
malnutrition, with gastrointestinal and extra-intestinal manifestations. The most common 
feature of celiac disease includes  gastrointestinal symptoms (i.e. abdominal pain, increased 
frequency of bowel movements), weight loss, bone disease, various degree of anemia and 
weakness.  
Different subtypes of celiac disease have been described. Symptomatic or classic celiac 
disease means typical gastrointestinal  symptoms with severe malabsorption syndrome. The 
term atypical celiac disease is applied to cases with mild or absent gastrointestinal 
symptoms (colitis or irritable bowel), and characterized by extra-intestinal manifestations, 
including iron deficient anemia, osteoporosis, failure to thrive. In both cases villous atrophy 
in observed during endoscopy or intestinal biopsies (Alaedini & Green, 2005). More recently 
it has been suggested to define celiac disease as silent, minor or major. Silent celiac disease is 
referred to asymptomatic subjects, sometimes relatives of patients with known celiac 
disease, or subjects eventually found to be positive at screening procedures. Minor celiac 
disease is referred to subjects with transient symptoms (dyspepsia, irritable bowel syndrome 
without malabsorption), anemia, cryptic hypertransaminasemia, infertility, peripheral and 
central neurological disorders, osteoporosis, dental enamel defects, failure to thrive, 
dermatitis herpetiformis. Major celiac disease is referred to patients with major 
gastrointestinal symptoms (Di Sabatino & Corazza, 2009).  
The mechanism underlying the severity of clinical presentation at present remains 
unknown. Researchers have shown that neither the degree of duodenal villous atrophy nor 
the extent of visible enteropathy assessed by capsule endoscopy correlates with presentation 
(Di Sabatino & Corazza, 2009).  
The recognition of a pre-celiac disease state is usually retrospective and this condition has 
been termed latent celiac disease.  
Potential celiac disease is characterized by positive antibodies but normal mucosa; there is no 
evidence to support managing these patients with a gluten-free diet. A higher prevalence of 
potential CD was found in patients with type 1 diabetes, and this observation may be 
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ascribed to the routine screening preformed in these patients, although the influence of 
genetic factors cannot be excluded. (Franzese et al., 2011). 
Refractory celiac disease is relatively rare complication occurring approximately from 2% to 
5% of patients. It is classified as persistent or recurrent symptoms of malabsorption and 
enteropathy. Refractory celiac disease is divided into two key categories, type I and type II.  
As regards celiac disease diagnosis, it has been demonstrated that case-finding by 
serological markers detection followed by histological confirmation on duodenal biopsy is 
an accurate, cost-effective and valid approach for diagnosis, in particular for high-risk 
subjects, like those affected by other autoimmune conditions, like type 1 diabetes mellitus.  
Celiac disease is associated with circulating antibodies against gliadin and endomysial 
tissue. Anti-endoMysial antibodies showed higher specificity and sensitivity than anti-
gliadin antibodies, and represent a useful means for screening procedures. Anti-reticulin 
antibodies screening showed less sensibility and it has been replaced by anti-endomysial 
antibodies. In 1997 the transglutaminase 2 enzyme was found to be the autoantigen for anti-
endomysial antibodies. Both anti-endomysial and anti-transglutaminase antibodies belong 
to the IgA class. The first are detected by immunofluorescence staining antibodies and 
results are qualitative or semiquantitative, while anti-transglutaminase antibodies are 
detected by an enzyme linked immunosorbent assay  (ELISA) or radioimmunoprecipitation, 
and the results are quantitative. Testing for IgG anti-transglutaminase and antibodies and, 
more recently for IgG anti-deaminated gliadin peptides are a useful alternative for patients 
with IgA deficiency (Di Sabatino & Corazza, 2009).  
In subjects with serological markers of celiac disease, a small intestinal biopsy is the “gold 
standard” for diagnosis. The finding of histological picture of villous atrophy with increased 
number of intraepithelial lymphocytes makes sure diagnosis of celiac disease, irrespective of 
serological markers result. The Marsh criteria (Marsh et al., 2005) are commonly used for 
histological staging. 
3.4 Treatment 
The only proven treatment for celiac disease is lifelong gluten-free diet. Foods containing 
gluten from wheat, rye, barley and their derivatives must be avoided since also small 
amounts of gluten are harmful. It has been reported that no more than 10 mg of gluten 
ingested  can be tolerated.  
Compliance to gluten-free diet is sometimes difficult, particularly during adolescence and 
for patients with silent celiac disease diagnosed by means of screening procedures. Dietary 
compliance can be evaluated through anti-endomysial and anti-deaminated gliadin 
antibodies detection. Complications of celiac disease are frequently observed in patients 
with delayed diagnosis and with poor compliance and include non-Hodgkin lymphoma, 
probably due to accumulation in the intestinal epithelium of aberrant and clonal 
intraepithelial lymphocytes (Al-Toma et al., 2007). Other complications include refractory 
celiac disease  and ulcerative jejunoileitis  (Rubio-Tapia et al., 2009).  
3.5 Celiac disease and type 1 diabetes mellitus 
That celiac disease prevalence is higher in patients with type 1 diabetes mellitus as 
compared to general population is universally accepted. After autoimmune thyroiditis, the 
second  most commonly reported autoimmune disease in type 1 diabetes is celiac disease 
(Van den Driessche, 2009).  
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Gluten consumption could be a common causative factor, as confirmed by the possible 
diagnosis of both diseases at the same time (Frisk et al. 2008). Moreover the duration of 
gluten exposure seems to increase the risk of other autoimmune diseases (Ventura et al.., 
1999). Dietary gluten could act as a modifier rather than a determinant causative factor, 
facilitating the progression of other dietary antigens to the small bowel lamina propria, 
where they can activate the immune response against -cells. Based on this hypothesis, the 
removal of gluten from diet has been proposed in subjects at risk as prevention trial to 
reduce the progression to type 1 diabetes mellitus (Pastore et al., 2003). A six-month of 
gluten-free diet in subjects at risk of type 1 diabetes did not influence -cells autoantibody 
titer, but only improved endogenous insulin secretion (Pastore et al., 2003).  
Recently, in samples from the small bowel mucosa from patients with celiac disease and 
type 1 diabetes a low expression of tight junction protein 1 (TJP1) mRNA has been observed, 
indicating an increase in intestinal permeability that might represent a causative factor. 
Furthermore, the highest expression of Forkhead box P3 (FoxP3) mRNA, a marker of 
regulatory T cells was observed, suggesting an increased immunoregolatory mechanisms 
(Uibo et al., 2011).  
The mean prevalence of celiac disease in type 1 diabetes is about 8%, with an extremely 
variable range (from 1% up to 11%) (Kakleas et al., 2010), almost 10-20 fold higher than 
observed in general pediatric population (Maki et al., 2003). The different prevalence data 
could be due to different screening  procedures and diagnostic tests used. The prevalence of 
celiac disease in type 1 diabetes increased over recent decade as compared to the past 
(Salardi et al., 2008), and seems to be related to changes in environmental factors like dietary 
habits or infectious diseases. Another possible explanation of this high association could be 
the same genotypes  involved in both diseases.. Three celiac disease loci, i.e. RGS1 on 
chromosome 1q31, IL18RAP on chromosome 2q12 and TAGAP on chromosome 6q25 were 
associated with type 1 diabetes mellitus. Moreover, the 32-bp insertion-deletion variant on 
chromosome 3p21, the PTPN2 on chromosome 18p11 and CTLA4 on chromosome 2q33 and 
SH2B3 on chromosome 12q24 are shared  by both diseases (Smyth et al., 2008). Younger age 
at diabetes clinical onset, female gender, and coexistence of another autoimmune disease are 
predictive factors for celiac disease development (Cerutti et al, 2004) 
In the majority of patients with type 1 diabetes clinical presentation of celiac disease is 
usually silent,  and thanks to screening procedure is diagnosed (Holmes, 2001, Barera et al, 
2002). On the other hand, a detailed medical history allows to identify several signs or 
symptoms attributable to celiac disease. Extra-intestinal manifestations such as failure to 
thrive, delayed puberty, iron-deficiency anemia, increased levels of liver enzyme tests, 
bleeding tendency, precocious osteoporosis, and unexplained hypoglycemic episodes are 
frequently reported. Gastrointestinal symptoms, i.e. diarrhea and abdominal pain, are 
reported in 28% and 14% of patients, respectively (Bhadada et al., 2011). Symptoms 
attributable to celiac disease are more common in children than in adolescents or adults 
(Larsson et al., 2008).  
Type 1 diabetes precedes celiac disease diagnosis (Holmes, 2001); in a small proportion (up 
to 25%) of cases  type 1 diabetes develops in already diagnosed celiac  patients (Valerio et 
al., 2002).  
In the majority of cases type 1 diabetes precedes celiac disease diagnosis (Holmes, 2001); in a 
small proportion of cases (up to 25%) type 1 diabetes develops in patients with already 
diagnosed celiac disease (Valerio et al., 2002).  
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Positivity for disease-related antibodies allows identification of patients with suspected 
celiac disease who must undergo intestinal biopsy. IgA-transglutaminase antibodies show 
the highest sensitivity and allow to identify around 98% of patients with celiac disease, 
while their specificity is lower, especially at a low titer (Salardi et al., 2008). IgA-anti-
endomysial antibodies show lower sensitivity (98%) but  higher  specificity. Fluctuating 
positivity for anti-endomysial antibodies at a low titer can be detected at time of diabetes 
clinical onset, and in absence of signs or  symptoms related to celiac disease only periodical 
screening is recommended .  
Total IgA screening is mandatory before celiac disease-related antibodies detection. Patients 
with IgA deficiency benefit from IgG anti-transglutaminase antibody detection (Lenhardt et 
al., 2004) and, as recently reported, by IgG anti-deaminated gliadin peptides (Volta et al., 
2010). IgA deficiency deserves attention, since this condition is more frequent in patients 
with celiac disease (1.7%) as compared to control population (0.25%)(Cataldo et al., 1997). 
As regards timing of screening, it has been reported that the serological screening of celiac 
disease allows diagnosing 1% of patients with celiac disease. The frequency of diagnoses 
increases to 5% when screening is performed in the next 5 years after diabetes diagnosis 
(Larsson et al., 2008).  It has been reported that up to 85% of cases of celiac disease is 
diagnosed 2-5 years after type 1 diabetes clinical onset  (Saukkonen et al., 1996). Markers of 
celiac disease can appear within 10 years, so it is recommended to perform screening yearly 
for the first 4 years after diabetes diagnosis, and every 2 years in the following 6 years 
(Kordonouri et al., 2009).  
 
 
Fig. 1. Linear growth in a girl with type 1 diabetes and concomitant celiac disease, who 
developed autoimmune thyroiditis  
Diagnosis of celiac disease by intestinal  biopsy requires a lifelong gluten-free diet.  Major 
problems related to gluten-free diet include quality of life, impairment of social life, poor 
compliance especially in adolescents and in patients with silent celiac disease diagnosed 
www.intechopen.com
 
Autoimmune Disorders Associated to Type 1 Diabetes Mellitus in Children and Adolescents 
 
11 
through screening procedures. Moreover, gluten-free diet can exert an increased insulin 
requirement since persistent hyperglycemia can occur. Gluten-free diet exerts in increased 
weight and height (Goh et al., 2010), as well as serum ferritin and hemoglobin (Hansen et al., 
2006). Moreover improvement of bone status in patients with type 1 diabetes and adherence 
to gluten-free diet has been reported (Valerio et al., 2008).  
4. Autoimmune thyroid disease 
4.1 Hashimoto’s thyroiditis 
4.1.1 Background and genetic susceptibility 
Autoimmune thyroid diseases include many thyroid gland disorders, with different 
histological and clinical pictures ranging from the hypothyroidism of chronic lymphocytic 
thyroiditis  to the hyperthyroidism of Graves’ disease.  
As other autoimmune diseases, chronic lymphocytic thyroiditis (also defined Hashimoto’s 
thyroiditis from the physician who firstly described this condition) derives from a 
combination of genetic susceptibility and some environmental trigger factors (Pearce et al, 
2003).   
Hashimoto’s thyroiditis is more frequent in females than in males (3.5 cases/1000 
people/year versus 0.8 cases/1000 people/year, respectively), and global prevalence is 
increasing with age.  
Hashimoto thyroiditis is the most common cause of acquired hypothyroidism in children 
and adolescents (formerly called “adolescent” or “simple” goiter), and usually presents 
itself during early adolescence or among schoolchildren, with or without gout, with a 
prevalence of 1% among schoolchildren (Lorini et al, 2003). 
Susceptibility to Hashimoto’s thyroiditis is determined by individual genetic background, 
including both major histocompatibility complex (MHC) and non-MHC genes. 
Associations have been reported between Hashimoto’s thyroiditis and HLA- DR3, HLA-
DR4, or HLA-DR5. Furthermore, in children and adolescents paternal alleles and antibodies 
status have been shown to influence susceptibility to autoimmune thyroid disease. The 
expression of HLA-DR antigens on thyroid cells have a potential role in perpetuating the 
immune response, related to certain HLA-DR subtypes. As regards non-HLA susceptibility 
genes, several studies demonstrated the association between a polymorphism of the CTLA-4 
gene and autoimmune thyroid disease (Barker, 2006). 
In literature are reported linkage with loci on the X chromosome and on chromosome 20 or 
14. Observations in twins are correlated with a genetic predisposition to thyroid 
autoimmunity. There are several cases of identical twins where one twin showed Graves’ 
disease and the others Hashimoto’s thyroiditis. It is common to find family clusters with HT 
and the incidence in parents or siblings of patient with HT can reach about 25% (Lorini et 
al., 2003). 
4.1.2 Pathogenesis   
There is no evidence that a clear infectious agent is responsible for autoimmune thyroiditis. 
However, long-term follow-up of patients with subacute thyroiditis showed a possible 
reaction to viral infection with signs of persistence thyroid autoimmune disease. To this 
purpose, hepatitis C can act as a trigger for the development of autoimmune thyroiditis 
through thyroid follicular cell apoptosis. Potential mechanisms of infectious triggers include 
cell damage with the release of auto-antigens, expression of new antigens and molecular 
mimicry mechanisms. 
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Drugs containing iodine or supplementary dietary iodine can trigger an autoimmune 
thyroiditis in subjects at risk, although the mechanism is still unknown. Accumulation of 
iodine in animal models leads to iodination of thyroglobulin which triggers an immune 
reaction because T-cell-reactive peptides can be more antigenic when iodinated.  Moreover 
dietary supplementation of iodine in the population of iodine-deficient regions such as the 
use of drugs rich in iodine (i.e.  amiodarone) induce cases of thyroiditis, and  a significant 
increase in lymphocytic infiltration by thyroid-specific auto-antibodies. Furthermore, 
patients treated with cytokines such as IL-1 or -interferon can trigger an autoimmune 
thyroiditis, which is more frequent in patients with pre-existing positivity for anti-thyroid 
auto-antibodies. 
Hashimoto's thyroiditis is an organ-specific autoimmune disease, characterized 
histologically by a lymphocytic infiltration of the thyroid gland,  initially characterized by  
hyperplasia and subsequently by infiltration of lymphocytes and plasma cells between 
follicles, then resulting in a follicle atrophy. Lymphocytic infiltration is composed of B 
lymphocytes, about 30%, and T-lymphocytes, about 60%, including CD4+ helper and CD 8+ 
suppressor. Autoimmune thyroiditis is characterized by thyroid cell apoptosis leading to 
follicular destruction, rather than thyroid stimulation and cellular hyperplasia. Thyroid 
gland is  infiltrated  by B- and T-lymphocytes, the later are capable of destroying thyroid 
cells, which express Fas, via apoptosis and release several cytokines that increase the 
damage. The process is exacerbated by the action of auto-antibodies directed against several 
thyroid antigens, like thyroid peroxidase antibodies (TPO-Abs), detectable in 90% of 
patients with Hashimoto’s thyroiditis,  previously considered non-pathogenic, but now their 
role has been shown. They inhibit enzyme activity and stimulate cytotoxicity by natural 
killer. Anti-thyroglobulin antibodies (TgA) are detectable in a small percentage of patients, 
while high levels of thyrotropin receptor-blocking antibodies are often present, particularly 
in patients who develop autoimmune hypothyroidism.  
4.1.3 Clinical picture 
Hashimoto's thyroiditis is the most common cause of acquired hypothyroidism in the 
pediatric population, occurring in about 1% of children and adolescents. Goiter is the 
hallmark of this autoimmune disease, and often may appear either insidiously or variable in 
size, however  is usually enlarged with accentuation of the normal lobular architecture. 
Occasionally goiter gives the sensation of local pressure or causes difficulty in swallowing. 
Hashimoto’s thyroiditis is more frequent in girls than in boys (four to seven times), with 
onset at 3 years but often sharply to 6 years with a peak incidence during adolescence. 
The most common clinical symptoms are related to hypothyroidism, and include 
deceleration in the rate of growth, although some children are apparently asymptomatic, 
and show abnormal values  in laboratory tests only. A few children complain clinical signs 
and symptoms of thyroid hyperfunction, such as nervousness, irritability, agitation, hot 
intolerance, weight loss. Eventually patient with Hashimoto’s thyroiditis can show 
ophthalmopathy in absence of Graves’ disease. The most frequent symptom in Hashimoto’s 
thyroiditis is goiter, followed by menstrual disorders, short stature, and nervousness in 
girls, while constipation and exophthalmos are more frequently reported in boys. Other 
signs are  hot and cold intolerance, weight loss or weight gain and sweating. The clinical 
course of Hashimoto’s thyroiditis is quite variable. In fact, the goiter may reduce or 
disappear, or persist unchanged for years, while the patient remains euthyroid or 
www.intechopen.com
 
Autoimmune Disorders Associated to Type 1 Diabetes Mellitus in Children and Adolescents 
 
13 
progressively develops hypothyroidism. Spontaneous remission is frequent in adolescents 
(Lorini et al, 2003). 
4.1.4 Laboratory findings 
In patients with autoimmune thyroiditis high serum levels of thyroid antibodies are present, 
therefore their detection is mandatory. Anti-thyroglobulin antibodies have been reported in 
60% of patients with diffuse goiter or hypothyroidism or both while anti-thyroid peroxidase 
antibodies are detectable in 95% of cases so they represent a more sensitive marker. In 20% 
of cases there are significant antibody titers in the absence of thyroiditis, while lower titer 
are related to other thyroid diseases and in normal population. 
Subclinical hypothyroidism means altered values of thyroid hormones in presence of a 
slightly or moderately elevated TSH. Many children with HT have normal level of TSH 
because the goiter is caused by lymphocytic infiltrations or growth-stimulating 
immunoglobulin. 
4.1.5 Imaging  
On imaging studies, the thyroid gland shows enlargement without specific characteristics. 
High resolution ultrasound may show hypoechogenic micronodules (Fig. 2). Scintigraphic 
findings are variable; in some patients with Hashimoto’s thyroiditis have thyroid gland 
enlarged with dysomogeneous distribution of tracer, in other cases the thyroid scan is 
normal but in most patients the uptake of radioiodine is decreased or increased. The 
perclorate washout is positive in 60% of patients. Often children and adolescents, evaluated 
at diagnosis, show a thyroid ultrasound picture altered.  The definitive diagnosis of HT is 
confirmed by a biopsy of the thyroid, that confirmed the elevated titers of thyroid 
autoantibodies in the serum. High serum TSH concentration can be found in  30-40% of 
cases, associated with  low serum T4, with normal or near-normal serum T3 concentration.  
Thyroid scan exclude thyroid dysgenesis. Elevated level of TSH clarifies if hypothyroidism  
is originated from pituitary or thyroid disease. 
 
 
Fig. 2. Hashimoto’s thyroiditis: thyroid ultrasound showing hypoechogenicity  
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4.1.6 Treatment  
The treatment of autoimmune thyroid follows the guidelines of congenital hypothyroidism. 
If the TSH level is greater than 10 μU/ml, L-thyroxin is the drug of choice. The initial dose is 
related on patient’s age and on patient’s clinical status from 25 μg/day to 100-150 μg/day. 
The therapy required periodic reevaluation, in particular when prominent nodules persist 
despite suppressive therapy, because there is a greater risk of cancer in patients with 
lymphocitic thyroiditis. 
4.2 Graves’ disease 
Graves' disease is the most important cause of thyrotoxicosis in pediatrics and affects about 
0.02% in children and adolescents. Its frequency increases with age: it is rare before the four 
years, gradually rises, reaching a peak during adolescence, with a preponderance for female 
gender (Kaguelidou et al, 2009). The aim of therapy is to reduce the excessive hormone 
production. First, this can be done with anti-thyroid drugs, as tionamides, with side effects 
especially after long-term therapy. Secondly, can be used thyroidectomy; however this 
surgical procedure may be complicated by several problems, such as hypoparathyroidism 
or recurrent nerve injury. Third method, is based on the use of radioiodine,  that has not 
been yet universally accepted in children. Initial treatment, is medication and in the second 
instance, surgery or radioiodine. The goal of treatment is to maintain euthyroidism for a 
period at least 24 month and then discontinue the medical therapy. The positive results, 
with pharmacological treatment alone reaches 25% of cases. In adults  the disease control is 
accomplished through the use of radioactive iodine or with drug for short periods. In 
children, however, use the medication for long periods, and then radioiodine,  is just as an 
alternative option. The average age of onset is at 11 years (from 2.5 to 19 years), with 
preponderance in girls and with more cases of exophthalmos, low BMI, and higher height 
SDS. The goal of treatment is to limit the biosynthesis of thyroid hormones and maintain 
euthyroidism by maintaining a check on lab tests. Adverse effects are recorded in 5-32% of 
cases with skin rashes, transient neutropenia and agranulocytosis. Children have more 
adverse effects but less severe, often reversible spontaneously or with therapy change. 
Alternatively, using radioiodine in patients with hyperthyroidism resistant to drug 
treatment of 4.5 years, there was more remission (about 25% between 2-4 years of follow 
up). Most side-effect of the therapy is a permanent hypothyroidism, which can be treated 
with replacement therapy. The problem of this method is a potential carcinogenic risk 
(thyroid cancer and leukaemia), that declines with age, genetic damage, and a possible 
damage to reproduction. Radioiodine for safety, low cost and morbidity, could be the 
definitive treatment of Graves’ disease in older children and young adolescents, but no in 
children younger than 5 years old (Gruneiro-Papendich et al, 2003).   
4.3 Autoimmune thyroid disease and type 1 diabetes 
Autoimmune thyroid disease is frequently reported in patients with type 1 diabetes 
mellitus, sometimes associated with celiac disease (Ergur et al, 2010). Serological screening 
studies  aimed to evaluate the prevalence of thyroid involvement have gained momentum 
in recent years (Kadiyala et al. 2010).  The prevalence of thyroid autoimmunity in patients 
with type 1 diabetes has been reported to be two to four times more frequent than in control 
population.  
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In control population the prevalence of thyroid autoimmunity ranges from 2.9% to 3.2%, 
while in young patients with type 1 diabetes the prevalence is higher, ranging from 19% to 
23.4% (Kakleas et al., 2009). In children and adolescents with type 1 diabetes, risk factors for 
developing thyroid autoimmunity are quite similar to those reported in adult population, 
and include mainly female gender and increasing age. The role of anti-glutamic acid 
decarboxylase antibody persistence, age at diabetes diagnosis and duration of diabetes 
remains unclear. At-risk haplotypes for autoimmune thyroiditis include HLA-DQA1*0301 
(linked to DR4), DQB1*0301 (linked to DR5) and DQB1*0201 (linked to DR3), which is 
associated with autoimmune hyperthyroidism, while the HLA-DQA1*0501 is associated 
with autoimmune hypothyroidism. The HLA haplotype DR3-DQB1*0201 confers the genetic 
susceptibility to type 1 diabetes mellitus, autoimmune thyroiditis and autoimmune 
polyendocrine syndrome type II. Finally, the HLA-haplotype DQB1*05 seems to be 
protective for  autoimmune thyroid disease development (Kakleas et al., 2009). Other loci, 
i.e. VNTR and CTLA-4  may influence disease phenotype and severity (Van Driessche et al., 
2009). 
A symmetric, painless goitre is usually the first presentation of autoimmune thyroid disease, 
while atrophic thyroid gland is observed in 10% of patients. A subclinical hypothyroidism 
has been reported up to 58% of patients with thyroid autoantibodies. Early recognition and 
treatment of hypothyroidism is important, since the decrease in basal metabolism may exert 
weight gain, dyslipidemia, atheroscleroticheart disease, sometimes goiter, and may 
negatively affect metabolic control. Hypothyroidism is confirmed by low free thyroxin and 
high TSH levels. Compensated hypothyroidism mean normal thyroxine levels with 
increased TSH. Substitutive L-thyroxin treatment exerts normalization of TSH levels and 
goitre regression when present.  Treatment with L-thyroxin in patients with type 1 diabetes, 
thyroid autoantibodies and thyroid enlargement is safe and effective to reduce thyromegaly, 
with no effect on thyroid autoantibodies titer (Brown, 2007, Kordonouri et al, 2007, Karges et 
al. 2007). 
Autoimmune thyroid disease and type 1 diabetes mellitus are sometimes associated with 
chronic urticaria, also in young patients, as a possible consequence of thyroid chronic 
inflammations. However the mechanisms underlying this association have not yet been 
defined, but this association emphasizes the need for a routine screening (Hyman et al., 2008). 
In young patients with type 1 diabetes mellitus overt hyperthyroidism is rarely 
encountered. It may be expression of Graves’ disease or the  transient hyperthyroid phase of 
Hashimoto’s thyroiditis. Unstable metabolic control despite strict compliance, weight loss 
despite regular food intake, agitation, tremors, tachycardia, insomnia, heath intolerance, 
thyroid enlargement and characteristic eye signs  are the main clinical features. Treatment is 
based on anti-thyroid drugs like propylthiuracil and metimazole.During acute 
thyrotoxicosis beta-adrenergic blockers agents are indicated. Persistent hyperthyroidism 
requires surgery or radioiodine (Kordonouri  et al, 2009).  
5. Atrophic gastritis 
5.1 Background 
While the association between type 1 diabetes and celiac disease and/or thyroid 
autoimmunity is clearly documented, particularly in young patients, few data are available 
about the frequency of other autoimmune diseases, like autoimmune gastritis and 
pernicious anemia. 
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Autoimmune gastritis,  firstly described by Thomas Addison in 1849,  is characterized by 
autoantibodies directed against gastric parietal cells,  atrophy of gastric corpus and fundus, 
hypochlorhydria/achlorhydria, hypergastrinemia, iron deficiency anemia and pernicious 
anemia.  
In adult general population the frequency of autoimmune gastritis is about 1-2%, and is 3-5 
fold increased in patients with type 1 diabetes (De Block et al, 2008). As regards children, 
adolescents and young adults with type 1 diabetes, the frequency of parietal cells antibodies is 
15.8%, with a close association with older age and duration of disease (De Block et al, 2008, 
Warncke et al, 2010).  Female gender association is controversial.    
5.2 Pathogenesis  
Antibodies against parietal cells (PCA) and their secretory product Intrinsic Factor (AIF) are 
serological markers for autoimmune gastritis and are targeted towards  H+, K+-ATPase of 
gastric parietal cells and denote autoimmune gastritis, characterized by atrophy of corpus 
and fundus. The chronic auto-aggression to the proton pump exerts in 
hypochlorhydria/achlorhydria and hypergastrinemia and iron-deficiency anemia as a 
consequence of impaired gastric secretion and iron absorption. Moreover PCA are 
responsible for the reduced intrinsic factor secretion with subsequent pernicious anemia due 
to vitamin 12 deficiency.  PCA and AIF are detectable not only in serum, but also in gastric 
juice. PCA titer is positively related to severity of gastric atrophy and negatively related to 
concentration of parietal cells. Low serum levels of pepsinogen I, as a consequence of chief 
cell destruction, represent another early marker of autoimmune gastritis  and pernicious 
anemia. Both pernicious anemia and autoimmune gastritis may predispose to gastric cancer. 
Gastric adenocarcinomas are reported on 1-10 % of adult patients with autoimmune gastritis 
through intestinal meta/dysplasia. (De Block et al., 2003) Helicobacter Pylori infection has 
been reported as a risk factor for autoimmune gastritis, by stimulating granulocytes to 
produce oxygen radicals, which are mutagenic and lead to corpus atrophy (D’Elios et al., 
2004). Molecular mimicry and/or T-helper l-induced expression of HLA-class II and co-
stimulatory molecules on gastric epithelial cells are considered as pathogenic mechanisms 
for Helicobacter Pylori induced autoimmunity  (Lahner et al., 2011). The evidence of a link 
between pernicious anemia and particular HLA haplo/genotypes is not strong. As regards 
type 1 diabetes, a weak association between PCA positivity and the HLA-DQA1*0501-
B1*0301 haplotype, linked to HLA-DR5, has been observed. In mouse models, four distinct 
genetic regions that confer susceptibility to autoimmune gastritis have been identified: two 
loci,  located on distal chromosome 4,  are called Gasa1 and Gasa2;  two other loci, located on 
chromosome 6, are called Gasa3 and Gasa4, respectively. Interestingly, three out of these four 
susceptibility loci are non-major histocompatibility complex genes which co-localize with 
those of type 1 diabetes. This is the strongest concordance identified between any two 
autoimmune disease so far (De Block et al., 2008). 
5.3 Diagnosis  
Parietal cell antibodies are measured using immunoblotting or enzyme linked immunoassay 
(ELISA), which are more sensitive than indirect immunofluorescence technique. Iron 
deficiency anemia is defined as microcytic hypochromic anemia with a transferrine 
saturation of less than 20% and low iron and ferritin levels. Pernicious anemia is defined as 
macrocytic anemia with subnormal vitamin B12 levels and positive levels of PCAs  
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Diagnosis of AG requires gastroscopy  with at least two   biopsies from gastric antrum and 
gastric body. Atrophy of the gastric body mucosa is defined as focal or complete oxyntic 
gland loss and/or replacement by metaplastic pylori or intestinal glands. To each graded 
variable, the scores usually employed are: 0 = absence; 1 = mild;  2 = moderate; 3 = severe  
(Bordi et al., 1997). 
5.4 Treatment  
Therapy of autoimmune gastritis includes supplementation of iron or vitamin B12 or 
removal of pre-malignant gastric lesions. Patients with PCA antibodies and high gastrin 
levels should undergo endoscopy with biopsies.  
Determining risk factors for and early diagnosis of autoimmune gastritis is mandatory to 
prevent and treat iron-deficiency anemia, pernicious anemia and pre-malignant gastric 
lesions.  In all PCA positive patients gastroscopy with multiple biopsies should be 
performed  and subsequent  clinical and endoscopic  close follow-up are mandatory. 
5.5 Autoimmune gastritis and type 1 diabetes 
Autoimmune gastritis is rarely encountered in children and adolescents with type 1 
diabetes, since the prevalence of parietal cell antibodies increases with age and with longer 
duration of disease. It is noteworthy that even young patients with type 1 diabetes are 
positive for parietal cell antibodies, with a frequency about 4%, which is higher than in 
controls (1.9%) (De Block et al., 2008). On the other hand, autoimmune gastritis is more 
frequent in children and adolescents with autoimmune thyroid disorder (Fig. 3 ).   
 
 
Fig. 3. Atrophic gastritis and sessile antral polyp with signs of esophageal candidiasis 
(personal data) 
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6. Addison’s disease 
6.1 Background  
In 1849 Thomas Addison firstly described a group of patients characterized by anemia and 
disease of adrenal glands. Addison's disease is an insidious, chronic disorder of the adrenal 
cortex resulting in decreased production of glucocorticoids, mineralocorticoids, and 
androgens. There is a concomitant increased secretion of ACTH from the pituitary gland 
aimed to stimulate the adrenal gland. In developed countries an autoimmune process is 
recognized as the most common etiological factor of adrenal gland insufficiency (70-90%); 
the second cause is tuberculosis of the adrenal gland (10 to 20%). Three clinical forms  of 
adrenal insufficiency are recognized: Addison disease within syndromes characterized by 
autoimmune involvement of several organs and named Autoimmune Polyendocrine 
Syndromes (APS-1 and APS-2), and Addison disease as an isolated condition. 
6.2 Pathogenesis 
Genetically predisposed individuals develop autoantibodies toward the 21-hydroxylase 
enzyme and eventually lose the ability to produce cortisol. Autoantibodies against 21-
hydroxylase are present in the majority of recently diagnosed  patients. Susceptibility is 
conferred through the genes encoding the class II Major Histocompatibility Complex. 
Similarly as for  type 1 diabetes mellitus, there is a strong association with the DR3 
haplotype. The highest risk genotype, occurring in 30% of patients with Addison's disease, 
is represented by DR3/4, DQ2/DQ8 and  the DRB1*0404 /DQ8-DRB1*0301/DQ2 genotype  
occurs at an increased frequency in individuals with isolated AD and in those with AD and 
type 1 diabetes mellitus   (El Fassi et al., 2007).  
6.3 Diagnosis 
Addison’s disease is preceded by a long prodromic, asymptomatic period, followed by 
subtle clinical manifestations up to adrenal insufficiency. Main symptoms are persistent 
vomiting, anorexia, hypoglycemia, unexplained weight loss, malaise, ill-defined fatigue, 
muscular weakness, hypotension, and craving for salt. The most specific sign of primary 
adrenal insufficiency is generalized hyperpigmentation of the skin and mucosal surfaces, as 
a consequence of high plasma concentrations of melanocyte stimulating activity of β-
lipotropin, which origins from the same precursor as ACTH. Laboratory tests can aid in the 
diagnosis: hypoglycemia,  hyponatriemia, hyperkaliemia, acidosis, high levels of ACTH and 
a deficiency of cortisol. Furthermore, adrenal antibodies represent a useful marker, with a 
higher predictive value in younger than in adult patient, being present in more than 90% of 
patients with autoimmune Addison disease. Antibodies are directed against steroidogenic 
enzymes (CYP21A2 and 21 hydroxylase) or adrenal cortex (Adrenal cortex autoantibodies, 
ACA). In addition, hypocorticism may cause frequent  hypoglycemic events (Van den 
Driessche et al 2009). We recommend screening patients with type 1A diabetes, 
hypoparathyroidism, and polyendocrine autoimmunity for 21-hydroxylase autoantibodies. 
If present, yearly monitoring with an ACTH stimulation test is performed to allow early 
diagnosis and prevent an adrenal crisis (Aaron et al., 2008). 
6.4 Treatment 
Addison’s disease treatment consists of urgent lifelong glucocorticoids replacement, with 
clear counseling about the need for stress dose steroids for illnesses and prior to surgical 
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procedures (Aaron et al., 2008). In some cases supplementation with mineralcorticoids in 
mandatory.  
6.5 Addison’s disease and type 1 diabetes 
In adolescents with type 1 diabetes Addison’s disease is rarely encountered, and  symptoms 
are sometimes aspecific. Addison’s disease usually follows type 1 diabetes diagnosis, being 
more frequently  observed within the Autoimmune Polyendocrine Syndrome type 1 and 
type 2 (Kordonouri et al., 2009). Correct diagnosis of Addison’s disease requires a high 
degree of clinical suspicion and since the disease is a life-threatening condition, several 
investigators recommend periodical screening of Addison’s disease in all young patients 
since type 1 diabetes  diagnosis (Brewer et al., 1997). In an adolescent with type 1 diabetes, 
Addison’s disease should be suspected in case of recurrent hypoglycemic episodes, 
unexplained decrease of insulin requirement and improvement of metabolic control, fatigue, 
weight loss, hyponatriemia and hyperkaliemia. Diagnosis confirmation requires low cortisol 
levels after ACTH stimulation test. Screening procedures allow to detect asymptomatic 
children and adolescents with positive adrenal antibodies; where raised ACTH levels 
suggest the presence of adrenal insufficiency. Risk factors for Addison’s disease in patients 
with type 1 diabetes include a history of other autoimmune conditions, in particular thyroid 
disease, and a positive family history for autoimmunity, as reported in a case series of 4 
adolescents with pre-existing type 1 diabetes who developed Addison disease (Thomas et 
al., 2004). Three out of 4 patients showed unexplained hypoglycemia and the other one 
showed unawareness hypoglycemia; all cases reported unexplained improvement in 
diabetes control.  Two out of 4 patients reported skin hyperpigmentation. In all 4 patients a 
positive personal and family history of other autoimmune conditions has been reported, in 
particular celiac and/or thyroid autoimmune diseases and Autoimmune Polyendocrine 
Syndrome type 2. A more recent study in 491 newly diagnosed children with type 1 diabetes 
aimed to define the prevalence of additional autoimmune conditions reported 1% positivity 
of antibodies to 21-hydroxylase, while overt Addison’s disease was found only in 20% of the 
positive patients (Triolo et al.; 2011). Noteworthy, all young patients with type 1 diabetes 
and adrenal autoantibodies develop Addison’s disease during the follow-up period, with a 
progression to overt adrenal failure much more rapid than in adults, indicating that 
different autoimmune responses may be evoked at different age periods (Betterle et al., 
1997).   
7. The Autoimmune Polyglandular Syndromes (APS) 
From the time of Addison’s original description of his disease onwards, it has been apparent 
that multiple autoimmune endocrine disease can affect individual patients and their families 
in recognizable clinical clusters.  
Twenty years ago, the autoimmune polyglandular syndromes (APS) were classified into 
three basic types based on the patient’s age at onset, their clinical associations with specific 
endocrinopathies and HLA typing. 
Type I APS, called also APECED (Autoimmune PolyEndocrinopathy-Candidiasis-
Ectodermal Dystrophy) is a rare autosomal recessive disorder originally identified through 
the typical association of mucocutaneous candidiasis with Addison’s disease and 
hypoparathyroidism. These symptoms usually constitute the first manifestation of the 
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disease in early childhood; other endocrine and non-endocrine disorders can be associated: 
thyroiditis, autoimmune hypogonadism, hypophysitis, chronic active hepatitis, atrophic 
gastritis, pernicious anemia, alopecia, vitiligo and ectodermal dystrophy (Mazza et al., 2011). 
The disease results from the inheritance of recessive genes (AIRE gene) mapping to 21q22.3 
and it is not linked to genes within the HLA-DR/DQ genetic region of chromosome 6.  
Type II APS is more common than type 1 APS, the prevalence is 1/20,000 with a female 
preponderance (male/female ratio = 1/3) and has a peak incidence between the ages of 20 
and 60 years, mostly in the third or fourth decade (Van den Driessche et al., 2009). It is 
defined by the association of Addison’s disease with thyroid autoimmunity, type 1 diabetes 
and sometimes pernicious anemia, vitiligo and hypogonadism. Type II APS is HLA-
associated (DQB1*0302/0201), while Hashimoto’s thyroiditis itself is associated with HLA-
DQB1*0301. Multiple antigens have now been identified for the component disease of type 
II APS ie: thyroperoxydase and thyroglobulin in Hashimoto’s thyroiditis; TSH receptors I 
Graves’ disease; insulin, GAD and IA-2 and IA-2B in type 1 diabetes mellitus; 21 
hydroxylase in Addison’s disease; 17 hydroxylase and SCC (all p450 enzymes) in 
hypogonadism; tyrosine in vitiligo; H+K+ATPase an intrinsic factor in pernicious anemia 
and the calcium sensing receptor (CaSR) in hypoparathyroidism. Indeed the autoantibody 
that reacts to CaSR does so through its external domain, suggesting that the respective 
autoimmunity (hypoparathyroidism) may be antibody dependent. In mice, such immune 
responses proceeded through a T cell helper-2 (Th2) pathway; whereas those that results in 
cell mediated pancreatic β-cell loss are though to occur through a Th1 pathway. It could be 
that APS I results from an inherited defective Th1 responsiveness resulting in uninhibited 
Th2 overactivity. On the other hand, APSII/III appears to results from Th1 autoimmunity, 
perhaps explaining why APS-I does not co-exist with APS-II or  III. 
CD4+ T helper (Th) cells play important roles in regulating immune responses including 
that of immunological tolerance to self. When these regulatory processes go away, one or 
more organ-specific autoimmune disease may develop. One prevailing theory developed in 
the mice is that immunoresponsiveness follows at least two polarized pathways. While one 
track (Th1) promotes cellular immune responses, the other (Th2) pathway favours antibody 
or allergic immunoresponsiveness. Such differentiated Th cells can be distinguished based 
upon their cytokine phenotypes.  
8. Conclusions 
It is now established that patients with type 1 diabetes are at increased risk of other 
autoimmune diseases as compared to general populations (Michels & Eisenbarth, 2010). 
Besides islet-cell autoantibodies, other antibodies against numerous non -cell antigens have 
been frequently reported. Clinically-evident diseases are rarely observed in young patients 
with type 1 diabetes, and can be considered as the tip of the iceberg. Latent forms of these 
autoimmune-associated diseases, characterized by the presence of circulating 
autoantibodies with mild or no  symptoms,  are more frequent.  Early detection of 
antibodies and latent organ-specific dysfunction are advocated to alert physicians to take  
appropriate actions aimed to prevent full-blown disease. Moreover patients and their 
relatives should be instructed to recognize subclinical signs and symptoms attributable to 
these autoimmune-associated diseases. Several risk factors have been identified for a group 
of autoimmune diseases like genetic background, gender, age, age at clinical onset and 
duration of diabetes.   
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